---
canonical_name: Sh-Polypeptide-11
alternate_names: rh-Oligopeptide-13, rh-Polypeptide-11, rh-FGF1, rh-aFGF, Acidic Fibroblast Growth Factor, aFGF, FGF1, CG-aFGF
canonical_topic: Sh-Polypeptide-11 for Hair Regrowth
short_topic_lc: sh_polypeptide_11_hair
creation_date: 2026-0628-0047
creator_ai_fullname: Opus 4.8
---
# Sh-Polypeptide-11 for Hair Regrowth
Evidence Review created on 06/28/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8
**Also known as:** rh-Oligopeptide-13, rh-Polypeptide-11, rh-FGF1, rh-aFGF, Acidic Fibroblast Growth Factor, aFGF, FGF1, CG-aFGF
## Motivation
Sh-Polypeptide-11 is a lab-made copy of a natural human signaling protein called acidic fibroblast growth factor (a messenger that tells skin cells to multiply and repair). It is made in cell cultures and added to topical serums for the scalp and skin. The interest for hair comes from a simple idea: the same signal that drives wound repair and the growth of skin-building cells might also coax resting hair follicles back into an active growing phase.
Growth-factor ingredients like this one have spread quickly through high-end hair serums, often marketed as a gentler alternative to standard hair-loss drugs. Most of the direct hair evidence so far comes from laboratory and animal work, where members of this protein family pushed resting follicles into growth. Human hair data specific to this ingredient remain very limited, the central tension this review addresses.
This review examines what is actually known about Sh-Polypeptide-11 applied to the scalp for hair regrowth: how it is thought to work, what the benefit and risk evidence shows, how it is typically used, and where the gaps in the evidence lie.
**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**
## Recommended Reading
This section lists high-level resources that give useful context on growth-factor peptides and hair regrowth for a non-specialist reader.
* [#316 – AMA #63: A guide for hair loss: causes, treatments, transplants, and sex-specific considerations](https://peterattiamd.com/ama63/) - Peter Attia
A structured clinician overview of androgenetic hair loss and its treatment options, useful for placing growth-factor serums within the broader, better-evidenced landscape of minoxidil, finasteride, and procedural therapies.
* [sh-Polypeptide-11 – CG-aFGF](https://ci.guide/peptides/sh-polypeptide-11) - Ghochikyan
An ingredient monograph that identifies Sh-Polypeptide-11 as recombinant acidic fibroblast growth factor and summarizes its proposed actions on fibroblasts, hair cells, and blood vessels, with primary references.
* [Sh-Polypeptide-11](https://www.stratiaskin.com/blogs/ingredients/sh-polypeptide-11) - Stratia
A plain-language formulator's explainer of what the ingredient is and why it is used, helpful for understanding how this growth factor is positioned in consumer products.
* [sh-Polypeptides: Growth Factors That Regrow Hair](https://www.juventudeskincare.com/blogs/founders-journal/growth-factor-complex-in-hair-serums-the-science-behind-sh-polypeptides-for-hair-growth) - Lindsey Walsh
A founder's overview distinguishing the various sh-polypeptide growth factors used in hair serums, clarifying how Sh-Polypeptide-11 differs from related FGF and KGF analogues.
* [Growth Factors in Hair Serum](https://xyonhealth.com/blogs/library/growth-factors-in-hair-serum) - Ciera Parsons
A clinically framed discussion of how growth factors in topical hair serums are proposed to work and what the human evidence does and does not yet support.
*Note: Of the five priority experts, only Peter Attia had directly relevant high-level content (on hair loss generally); no priority-expert content named this specific ingredient. Five eligible items were found, so the list is complete and not padded.*
## Grokipedia
No Grokipedia article exists for Sh-Polypeptide-11.
## Examine
No Examine article exists for Sh-Polypeptide-11. Examine.com focuses on orally ingested supplements and does not typically cover topical recombinant growth-factor peptides.
## ConsumerLab
No ConsumerLab article exists for Sh-Polypeptide-11. ConsumerLab tests and reviews ingestible supplements and does not typically cover topical recombinant growth-factor peptides.
## Systematic Reviews
No systematic reviews or meta-analyses for Sh-Polypeptide-11 were found on PubMed as of June 28, 2026.
## Mechanism of Action
Sh-Polypeptide-11 is a recombinant (lab-produced) form of acidic fibroblast growth factor 1 (FGF1, a natural protein that signals cells to grow and divide). It binds to fibroblast growth factor receptors (FGFRs, docking proteins on the cell surface) on several cell types in skin and the hair follicle, switching on internal signaling cascades that drive cell proliferation and survival.
The primary proposed pathway for hair is induction of the **anagen** (active growth) phase. In animal work, members of this protein family drove resting follicles back into growth by activating the **Wnt/β-catenin** signaling pathway (a master switch for follicle stem-cell activation) and **Sonic hedgehog (Shh)** signaling (a pathway that drives follicle downgrowth and matrix-cell division). FGF1 also acts on **dermal papilla cells** (the signaling hub at the base of the follicle that instructs surrounding cells to grow); activated dermal papilla cells then stimulate proliferation of the outer root sheath cells that form the growing hair.
A second proposed contribution is improved local blood supply. FGF1 stimulates proliferation of vascular endothelial cells, which could enhance the small-vessel network feeding the follicle, though the angiogenic signal for FGF1 specifically has been modest and not always statistically significant.
A competing mechanistic view tempers these claims. The FGF family contains both growth-promoting and growth-inhibiting members — FGF5, for example, actively drives follicles out of anagen and into regression, and it can reverse FGF1-driven follicle stimulation. This means the net effect of manipulating one FGF depends on the surrounding signaling context, and a pro-growth signal in a dish or a mouse may not translate to net regrowth on a human scalp. A further limitation is delivery: the intact protein is large and does not readily cross the skin barrier, so any scalp effect depends heavily on the formulation (for example, liposomal encapsulation).
As a recombinant protein rather than a small-molecule drug, classic pharmacological parameters apply differently. Native FGF1 has a short circulating half-life (on the order of minutes once systemic), is not metabolized by cytochrome P450 liver enzymes, and acts locally at the application site. It binds heparin and heparan sulfate in the extracellular matrix, which stabilizes it and modulates its receptor binding; selectivity is broad across FGFR subtypes rather than tissue-specific.
## Historical Context & Evolution
Acidic fibroblast growth factor (FGF1) was first characterized in the 1970s–1980s as a potent mitogen — a substance that drives cell division — for cells of skin origin, including keratinocytes, fibroblasts, and blood-vessel cells. Its original intended use was therapeutic: as a wound-healing and tissue-repair agent. Early rodent studies showed that topically applied acidic FGF nearly doubled the rate of closure of full-thickness skin wounds, and recombinant human acidic FGF was later studied in humans for burns and skin-graft donor sites.
The move toward hair and cosmetic use grew out of two observations. First, the same proliferative signals that speed wound repair also govern the hair follicle, which is itself a regenerating mini-organ; immunostaining studies localized acidic FGF to developing and growing follicles. Second, the broader longevity-oriented and growth-factor skincare movement created a commercial pathway: once recombinant production made the protein available, it was reformulated under cosmetic naming conventions (the INCI name Sh-Polypeptide-11, trade name CG-aFGF) and incorporated into longevity-oriented skin and hair serums.
The actual historical findings are mixed rather than uniformly positive. Animal and follicle-culture studies consistently show that acidic FGF can stimulate follicle cells and induce anagen, but the same body of work also identified FGF5 as an opposing, anagen-terminating signal within the same family. Rather than being "debunked," the early pro-hair findings stand as valid but narrow: they establish a plausible biological signal without demonstrating net human scalp regrowth.
Scientific opinion continues to evolve. A 2025 review of FGF signaling in hair argued that targeting this pathway could eventually exceed current treatments in efficacy and safety, while emphasizing how much of the receptor biology in human follicles remains underexplored. The current position is therefore best read as an open, mechanistically promising question rather than a settled conclusion in either direction.
## Expected Benefits
### Speculative 🟨
#### Stimulation of Hair Regrowth (Increased Density)
The central marketed benefit is that topical Sh-Polypeptide-11 reactivates resting follicles and increases hair count or density. The mechanistic basis is real: in telogen-phase mice, topical FGF family members (including acidic FGF) induced an earlier and prolonged anagen phase with early activation of β-catenin and Sonic hedgehog in follicles. However, there are no published controlled human trials of Sh-Polypeptide-11 (or isolated acidic FGF) demonstrating increased hair density on the human scalp; consumer claims of percentages of users gaining terminal hairs come from unpublished or marketing sources and cannot be independently verified. The evidence basis is therefore mechanistic and preclinical (animal) only.
#### Prolongation of the Active Growth (Anagen) Phase
Beyond simply initiating growth, acidic FGF may extend the duration of the anagen phase, which would translate to longer, thicker hairs. In cultured wool follicles, acidic FGF altered the differentiation program of fiber-producing cells, and in mice it lengthened the mature anagen phase. This benefit shares the same limitation as overall regrowth: it rests on animal and ex-vivo follicle data, with no controlled human scalp evidence specific to this ingredient.
#### Protection of Follicles from Stress-Induced Loss
A distinct potential benefit is follicle protection rather than de-novo regrowth. In a mouse model, acidic FGF (FGF1) reduced radiation-induced apoptosis (programmed cell death) of hair-follicle cells, preventing the premature shift from growth to regression. This suggests a possible role in limiting shedding under follicular stress, but the data are from a single non-scalp, non-androgenetic animal model and do not establish a human benefit.
#### Improved Scalp Microcirculation and Skin Quality
By stimulating blood-vessel and fibroblast proliferation, Sh-Polypeptide-11 is proposed to improve the local environment around follicles (better microcirculation, firmer surrounding dermis), indirectly supporting hair. This draws on its established wound-healing and dermal-firming actions, where human topical data exist for skin (not hair). The angiogenic effect of FGF1 specifically has been reported as small and not always statistically significant, so any contribution to hair is indirect and unproven, and the basis is mechanistic and extrapolated.
## Benefit-Modifying Factors
The following factors may plausibly influence whether any benefit is realized, though none have been formally tested for this ingredient in human hair:
* **Cause and stage of hair loss:** Follicles that are dormant but viable (early androgenetic or telogen-phase thinning) are more likely to respond to an anagen-inducing signal than follicles that are scarred or fully miniaturized; advanced, long-standing baldness is unlikely to respond.
* **Formulation and delivery:** Because the intact protein does not cross the skin barrier well, benefit depends heavily on the delivery system (e.g., liposomal encapsulation, microneedling-assisted delivery). An identical concentration in a poorly penetrating vehicle may produce no effect.
* **Baseline scalp and vascular health:** A healthy, well-perfused scalp with intact follicular stem-cell pools provides the substrate the growth factor acts on; chronic inflammation, fibrosis, or poor microcirculation would blunt response.
* **Sex-based differences:** Patterned hair loss differs by sex in distribution and hormonal drivers, and growth-factor responsiveness has not been characterized separately in men and women; any sex difference in response to Sh-Polypeptide-11 is currently unknown.
* **Age:** Older follicles have reduced stem-cell activity and regenerative capacity, and growth-factor signaling itself declines with age, so older individuals at the upper end of the target range may respond less robustly than younger ones.
* **Concurrent therapy:** Effects may be larger when combined with established treatments or procedures (microneedling, minoxidil), as growth factors are most often studied as add-ons rather than standalone agents.
## Potential Risks & Side Effects
### Low 🟥
#### Local Skin Reactions (Irritation, Redness, Itching)
As with most topical serums, the most likely adverse effects are application-site reactions: mild irritation, redness, itching, or stinging, driven more often by the overall formulation (solvents, preservatives, fragrance) than by the peptide itself. Recombinant acidic FGF used topically in controlled wound-healing and burn studies was generally well tolerated without notable local toxicity. Such reactions are usually mild, reversible on discontinuation, and comparable to other peptide-containing cosmetics.
**Magnitude:** Mild application-site reactions are uncommon, on the order of a few percent of users (roughly 1–5%) by analogy to topical peptide and growth-factor serums, with serious local toxicity not reported in topical recombinant acidic FGF wound-healing studies.
### Speculative 🟨
#### Allergic or Hypersensitivity Response to a Recombinant Protein
Because Sh-Polypeptide-11 is a protein produced in a microbial or cell-culture system, there is a theoretical risk of allergic sensitization or hypersensitivity to the protein or to trace host-cell or process residues. No confirmed cases tied specifically to this cosmetic ingredient are documented, so the concern is mechanistic and precautionary rather than evidence-based, and would be expected to present as localized contact-allergy symptoms.
#### Theoretical Pro-Proliferative / Tumor-Promotion Concern
Growth factors stimulate cell division, which raises a theoretical concern about promoting growth of pre-existing abnormal or pre-cancerous cells in treated skin. This concern is frequently raised for growth-factor skincare in general. For topically applied Sh-Polypeptide-11 the protein's poor skin penetration and local action argue against meaningful systemic exposure, and no human evidence links cosmetic use to cancer; the concern remains hypothetical and unquantified, based on the general biology of mitogens rather than on reports.
#### Unintended Effects from Broad FGF Signaling
Because FGF receptors are widely expressed and the FGF family contains opposing growth and regression signals, an exogenous FGF could in principle produce unpredictable follicular effects (for instance, no benefit or paradoxical responses if the local signaling context favors regression). This is a mechanistic caution drawn from the existence of anagen-terminating family members such as FGF5; it has not been observed as a documented adverse event for this ingredient.
## Risk-Modifying Factors
The following factors may modify the likelihood or severity of adverse effects, though none are formally characterized for this ingredient:
* **Genetic predisposition to skin reactivity:** No pharmacogenetic variant has been validated to modify the risk of topical Sh-Polypeptide-11 specifically, but polymorphisms in filaggrin (FLG, a gene governing the skin barrier) predispose to barrier impairment and atopic/contact dermatitis, plausibly raising irritation and sensitization risk; this is extrapolated from general dermatology rather than ingredient-specific data.
* **Sensitive or compromised skin:** Individuals with eczema, rosacea, seborrheic dermatitis, or a broken scalp barrier are more prone to irritation and to greater (and less predictable) absorption of the protein and excipients.
* **Personal history of contact allergy:** A history of reactions to cosmetic peptides, preservatives, or fragrances raises the baseline risk of a hypersensitivity reaction; patch testing reduces this risk.
* **Pre-existing or prior skin cancers:** Given the theoretical pro-proliferative concern, those with a history of skin malignancy or active pre-cancerous lesions in the application area have a more cautious risk profile, even though no causal link is established.
* **Baseline biomarkers:** No specific laboratory biomarker predicts topical risk; assessment is clinical (skin condition, allergy history) rather than lab-based.
* **Sex-based differences:** No sex-specific safety differences have been characterized for topical Sh-Polypeptide-11.
* **Age:** Older or photoaged, thinner skin may be marginally more reactive to topical actives, though this is a general dermatologic consideration rather than an ingredient-specific finding.
## Key Interactions & Contraindications
Because Sh-Polypeptide-11 is applied topically to the scalp and is poorly absorbed systemically, classic systemic drug–drug interactions are unlikely. Relevant interactions are mostly local and formulation-level.
* **Prescription topical interactions:** Topical retinoids (tretinoin, adapalene) and other potentially irritating prescription topicals applied to the same area can compound scalp irritation; severity is caution-level, and the consequence is additive local irritation. Mitigating action: separate application times or alternate days.
* **Over-the-counter topical interactions:** Concurrent exfoliating acids (glycolic, salicylic acid) or benzoyl peroxide on the scalp may degrade the peptide or increase irritation; severity caution, consequence reduced efficacy and additive irritation. Mitigating action: apply at different times of day.
* **Supplement interactions:** No meaningful systemic supplement interactions are expected. Topical antioxidant serums (e.g., high-strength vitamin C at low pH) applied simultaneously could chemically destabilize the protein; severity is minor (loss of efficacy, not harm). Mitigating action: separate application.
* **Additive (potentiating) combinations:** Other topical hair actives are commonly layered for additive effect — minoxidil (a vasodilator hair-growth drug), other growth-factor peptides (e.g., sh-Polypeptide-1/bFGF, copper tripeptide), and procedural delivery such as microneedling. These may enhance results but also increase total irritation load.
* **Other intervention interactions:** Microneedling and energy-based procedures markedly increase skin penetration of the peptide; this is a potentiating interaction that can raise both efficacy and irritation/absorption, and should be approached cautiously.
* **Populations who should avoid it:** Pregnant or breastfeeding individuals (no safety data; growth-factor signaling is a theoretical concern), people with active scalp infection, open wounds, or inflammatory scalp disease at the site, anyone with a known allergy to the product or its components, and those with active or recent skin cancer in the treatment area as a precaution.
## Risk Mitigation Strategies
* **Patch test before first scalp use:** Apply a small amount to a discreet area (e.g., inner forearm or behind the ear) for several days before scalp-wide use to screen for irritation or allergy, mitigating the risk of a hypersensitivity or contact-irritation reaction over a large area.
* **Start with lower frequency and titrate:** Begin once daily (or every other day) rather than twice daily for the first 1–2 weeks, increasing only if well tolerated, to reduce the risk of cumulative irritation, redness, and itching.
* **Separate from irritating actives:** Apply at a different time of day from retinoids, exfoliating acids, or benzoyl peroxide on the scalp to mitigate additive irritation and to avoid chemically degrading the peptide.
* **Avoid use on broken or inflamed scalp:** Do not apply over open wounds, active infection, or flaring dermatitis, which increases absorption and irritation risk; treat the underlying scalp condition first.
* **Use caution with enhanced-delivery procedures:** When combining with microneedling, follow conservative needle depths and frequencies and allow skin to recover between sessions, mitigating the increased absorption and irritation that aggressive delivery can cause.
* **Precaution in higher-risk individuals:** Pregnant/breastfeeding individuals and those with a history of skin cancer in the area should avoid use or seek individualized guidance, mitigating the theoretical pro-proliferative and unknown-developmental risks.
## Therapeutic Protocol
There is no standardized, evidence-based clinical protocol for Sh-Polypeptide-11 in hair regrowth; usage is defined by cosmetic product instructions and practitioner convention rather than by trials. The patterns below reflect how it is typically used.
* **Standard application:** A leave-on serum containing the peptide (often within a multi-growth-factor or peptide complex) is applied to the affected scalp areas, typically once or twice daily, and left on. This mirrors the regimen used in the closest comparable clinical context (peptide hair serums evaluated against minoxidil).
* **Competing approaches — standalone vs. adjunctive:** One approach uses growth-factor serums as a standalone daily cosmetic regimen; another uses them as an adjunct to established treatments (minoxidil, finasteride) or to procedures (microneedling, fractional laser, platelet-rich plasma). Neither is established as superior for this ingredient; growth factors are most often studied as part of combination protocols rather than as monotherapy.
* **Practitioner context:** Aesthetic and trichology clinics popularized layering growth-factor serums with microneedling or fractional-laser sessions to improve delivery; the cosmetic-ingredient literature (e.g., CG-aFGF positioning) frames the peptide as a high-end serum active rather than a clinic-only therapy.
* **Best time of day:** No circadian timing advantage is established. Practical guidance is to apply to a clean, dry scalp and to avoid washing the area for several hours afterward to allow contact time; if used with other actives, separate by time of day.
* **Half-life consideration:** As a recombinant protein, native acidic FGF has a short biological half-life (minutes systemically) and acts locally and transiently; this short window is part of the rationale for once- or twice-daily reapplication and for delivery systems that prolong follicular contact.
* **Single vs. split dosing:** Because the protein acts locally and briefly, twice-daily (split) application is commonly used to maintain follicular exposure rather than a single daily dose, though no comparative data establish the optimal frequency.
* **Genetic considerations:** No pharmacogenetic variants (e.g., affecting FGF-receptor signaling) have been validated to guide dosing of topical Sh-Polypeptide-11; genetic sensitivity to androgens (the main driver of patterned loss) is more relevant to overall strategy than to this peptide specifically.
* **Sex-based differences:** Dosing is not differentiated by sex in available products; patterned hair loss differs by sex, but no sex-specific dosing for this peptide is established.
* **Age-related considerations:** Older individuals with reduced follicular regenerative capacity may see smaller responses; protocol intensity (frequency, adjuncts) is sometimes increased empirically, without supporting trial data.
* **Baseline biomarkers and conditions:** No biomarker-guided dosing exists; baseline scalp assessment (follicle viability, inflammation, miniaturization) informs realistic expectations more than dose. Pre-existing scalp disease should be addressed before starting.
## Discontinuation & Cycling
* **Lifelong vs. short-term:** Like most hair-growth maintenance approaches, any benefit is presumed to depend on continued use; the underlying drivers of patterned hair loss persist, so stopping is expected to allow gradual reversion over subsequent hair cycles. There is no defined treatment course after which results become permanent.
* **Withdrawal effects:** No specific withdrawal syndrome is documented for Sh-Polypeptide-11. Unlike vasodilator drugs, abrupt cessation is not expected to cause acute shedding; any loss would reflect the natural return of follicles to their pre-treatment trajectory rather than a rebound effect.
* **Tapering:** No tapering protocol is established or considered necessary, given the absence of a withdrawal effect; the product can generally be stopped without a step-down.
* **Cycling:** There is no evidence that cycling (planned on/off periods) preserves efficacy or prevents tolerance for this peptide; receptor-level tachyphylaxis (diminishing response) has not been characterized, so cycling is neither supported nor clearly contraindicated.
## Sourcing and Quality
* **Recombinant origin and identity:** Quality starts with verified identity — genuine Sh-Polypeptide-11 is a recombinant acidic FGF1 protein (INCI Sh-Polypeptide-11; trade name CG-aFGF; FDA UNII G53298VN9Y). Products should list the INCI name accurately and ideally state purity and that the protein is produced under controlled fermentation/cell-culture conditions.
* **Formulation and delivery system:** Because the intact protein penetrates skin poorly, look for a delivery strategy (e.g., liposomal encapsulation) and an appropriate, stable vehicle; the same concentration in a poorly designed base may be ineffective. Concentration alone is a weak quality indicator without a delivery rationale.
* **Stability and storage:** Proteins are heat- and oxidation-sensitive. Reputable products use protective packaging (opaque, air-restricting) and may recommend refrigeration; check for stabilizers and avoid products with no stability provisions or that have been exposed to heat.
* **Third-party testing and manufacturer credibility:** Prefer formulations from manufacturers that disclose sourcing, provide batch consistency, and ideally offer third-party verification of identity and purity; growth-factor ingredients vary widely in quality, and marketing claims often outrun verified content.
* **Reputable formulators:** Cosmetic-science-oriented brands that publish ingredient rationales (e.g., those using established CG-aFGF/peptide complexes) and compounding-grade suppliers are preferable to anonymous marketplace serums with unverifiable claims.
## Practical Considerations
* **Time to effect:** Hair cycles are slow; any visible change would be expected over months, not weeks. By analogy to peptide and growth-factor hair-serum studies, meaningful assessment typically occurs at roughly 12 and 24 weeks of consistent use, and results should not be judged before about three months.
* **Common pitfalls:** Frequent mistakes include expecting drug-level results from a cosmetic, judging too early, using a product with no credible delivery system, applying inconsistently, and assuming a growth-factor serum can replace established treatments (minoxidil, finasteride) rather than complement them.
* **Regulatory status:** In the United States and most markets, Sh-Polypeptide-11 is sold as a cosmetic ingredient, not an approved drug for hair regrowth; it is not FDA-approved to treat androgenetic alopecia, and hair-growth claims for cosmetics are not held to drug-level evidence standards. Recombinant acidic FGF has separately been studied as a medical wound-healing agent in some countries.
* **Cost and accessibility:** Growth-factor serums are typically positioned at the premium end of the hair-care market and can be considerably more expensive than generic minoxidil, which is relevant given the limited efficacy evidence; accessibility is otherwise good as an over-the-counter cosmetic.
## Interaction with Foundational Habits
* **Sleep:** The interaction is indirect/none. There is no known mechanism by which a topically applied, poorly absorbed scalp protein affects sleep, and no evidence that sleep timing alters its local action. Sleep supports overall hair health generally, but no specific practical timing consideration applies to this peptide.
* **Nutrition:** The interaction is indirect. Sh-Polypeptide-11 does not deplete nutrients or require a specific diet. However, follicle response to any pro-growth signal depends on adequate substrate; correcting deficiencies relevant to hair (notably iron/ferritin, protein, and overall caloric adequacy) plausibly supports any benefit, while no food needs to be avoided around topical use.
* **Exercise:** The interaction is largely none/indirect. Exercise does not blunt or potentiate a topical scalp peptide in any established way. A practical consideration is timing relative to sweating: applying the serum after exercise and scalp washing (rather than before heavy sweating) avoids dilution or premature removal.
* **Stress management:** The interaction is indirect. High chronic stress can push follicles toward shedding (telogen effluvium) and may counteract a pro-growth signal; managing stress addresses an upstream driver of hair loss rather than interacting with the peptide directly. No effect of this topical on cortisol or the stress response is described.
## Monitoring Protocol & Defining Success
Because Sh-Polypeptide-11 is a topical cosmetic with minimal systemic absorption, formal laboratory monitoring is not required for the ingredient itself. The most useful monitoring is structured assessment of the hair response and of any underlying, treatable drivers of hair loss. Baseline evaluation before starting establishes a reference point (standardized scalp photographs, hair density/diameter, and a baseline check of common reversible contributors). Where labs are used, they target underlying causes of hair loss rather than effects of the peptide.
The lab tests below are optional and aimed at identifying correctable contributors to hair loss before attributing success or failure to the serum. A reasonable cadence is to obtain any relevant baseline labs once before starting, then re-test only if clinically indicated; objective hair assessment (photographs, density) is most useful at baseline, then at roughly 12 weeks, 24 weeks, and every 6 months thereafter.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
| --- | --- | --- | --- |
| Ferritin (iron stores) | 50–70+ ng/mL | Low iron stores are a common, reversible driver of hair shedding | Conventional "normal" starts ~15–30 ng/mL, well below the functional hair threshold; fasting not required |
| TSH (thyroid-stimulating hormone) | ~0.5–2.5 mIU/L | Thyroid imbalance is a frequent treatable cause of diffuse hair loss | Conventional upper limit (~4.0–4.5) is higher than the functional target; best paired with free T4 |
| Vitamin D (25-hydroxyvitamin D) | 40–60 ng/mL | Low vitamin D is associated with hair-cycle disruption | Conventional "sufficient" starts at 30 ng/mL; no fasting needed |
| Total testosterone & DHEA-S | Sex- and age-appropriate optimal range | Androgen excess (especially in women) signals an androgen-driven component that a growth factor will not address | Best drawn in the morning; abnormal results warrant evaluation of the primary driver |
| Zinc | Upper half of reference range | Zinc deficiency can contribute to hair loss and impaired follicle function | Often paired with ferritin and vitamin D; trace-element handling matters for sample quality |
Qualitative markers are often more informative than labs for tracking a cosmetic hair serum:
* Reduced daily shedding (e.g., fewer hairs in the brush, shower, or on the pillow)
* Increase in fine "regrowth" hairs along the hairline or part, then their thickening into coarser hairs over months
* Subjective scalp coverage, part width, and ponytail thickness
* Overall scalp comfort and absence of irritation as a tolerability marker
Success is best defined conservatively for this ingredient: stabilization of shedding and modest visible improvement in density/coverage over 3–6 months on standardized photographs, with good tolerability — recognizing that strong regrowth comparable to established drugs should not be the default expectation.
## Emerging Research
* **Peptide-factor hair serum vs. minoxidil (active trial):** A randomized, double-blind trial ([NCT07536100](https://clinicaltrials.gov/study/NCT07536100)) is comparing a peptide-factor hair serum against 2% topical minoxidil in 80 adults with androgenetic alopecia over 24 weeks, with hair density and diameter as endpoints. It is the closest registered test of the growth-factor/peptide-serum approach this ingredient belongs to, and could either strengthen or weaken the case depending on whether peptide serums match minoxidil.
* **FGF-pathway hair biology (recent review):** A 2025 review of fibroblast growth factors in hair-follicle growth ([Wang et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40867641/)) argues the FGF/FGFR pathway is a promising and underexplored therapeutic target that could exceed current treatments, while flagging how much human follicle receptor biology is still unknown — a direction that could strengthen the rationale if translated.
* **Mechanistic anagen-induction evidence (foundational):** The key animal finding that FGFs, including acidic FGF, induce anagen via β-catenin and Sonic hedgehog ([Lin et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25685806/)) remains the strongest pro-hair signal; replication and, critically, translation to controlled human scalp studies is the research most likely to change current understanding.
* **Follicle-protection direction (counter/complementary evidence):** Work showing acidic FGF reduces follicle-cell death under stress ([Nakayama et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19469896/)) points toward a protective rather than purely regrowth role; whether this protective effect occurs in human androgenetic loss is an open question that could broaden or narrow the indication.
* **Cosmetic-peptide evidence appraisal (skeptical direction):** A 2025 review of topical hair-loss actives ([Bikash, 2025](https://pubmed.ncbi.nlm.nih.gov/40654553/)) catalogs the limited, conflict-of-interest-prone evidence behind hyped cosmetic hair peptides and argues they are best seen as add-ons; this line of work could weaken standalone claims for growth-factor serums if rigorous comparative trials remain absent.
## Conclusion
Sh-Polypeptide-11 is a lab-made copy of a natural human growth signal (acidic fibroblast growth factor) added to topical scalp and skin serums. The idea behind it is biologically reasonable: this signal pushes resting hair follicles toward active growth and supports the cells and blood vessels around them. In laboratory and animal studies, this family of growth signals did reawaken dormant follicles and lengthen the active growth phase, and one related effect may help protect follicles from stress-related loss.
The gap is in human proof. There are no published, controlled human studies showing that this specific ingredient regrows scalp hair, so its main benefits remain promising rather than demonstrated. The same signaling family also contains an opposing factor that ends hair growth, and the protein is large and hard to absorb through skin, so results depend heavily on the product's delivery system. On safety, topical use appears generally well tolerated, with mild local irritation the most likely issue and only theoretical concerns beyond that.
Overall, the evidence base is thin and leans on mechanism and animal work rather than human outcomes, and several sources promoting it have a commercial interest. It is best understood as an early-stage, plausible add-on whose real-world effect on human hair is not yet established.
**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**